Martin Driscoll

Apr 07, 2015

MetaStat appointed Martin Driscoll to its board, effective immedicately. Since 2010, Driscoll has been president and CEO of Asmacure, which develops small molecule cholinergic receptor modulators for treating pulmonary diseases. Prior to that, he was CEO of Javelin Pharmaceuticals. He also was at Schering-Plough for 18 years where he held various global general management positions.